<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215849</url>
  </required_header>
  <id_info>
    <org_study_id>203878</org_study_id>
    <nct_id>NCT03215849</nct_id>
  </id_info>
  <brief_title>Pacing in Heart Failure With Preserved LVEF</brief_title>
  <official_title>The Effect of Biventricular Pacing in Heart Failure With Preserved Left Ventricular Ejection Fraction: A Pilot Mechanistic Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of East Anglia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of East Anglia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A random-order cross-over pilot trial of a CE marked device (pacemaker) outside its current&#xD;
      intended purposes.&#xD;
&#xD;
      The study will comprise 10 patients. Recruitment of patients will take place from The&#xD;
      University Hospital of Wales (Cardiff &amp; Vale University Health Board [CVUHB]). All patients&#xD;
      recruited will have septal flattening during exercise demonstrated using contrast stress&#xD;
      (exercise) echocardiography.&#xD;
&#xD;
      All 10 patients will be implanted with a CRT-pacemaker device and will be tested on all three&#xD;
      of the following settings on separate visits (with a gap of up to 5 days between visits) in&#xD;
      random order:&#xD;
&#xD;
      Routine Medical Therapy Routine Medical Therapy + LVP Routine Medical Therapy + BiVP&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in septal radius of curvature (corrected for LV area) between rest and peak exercise on stress echocardiography across the three pacing states.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LV area between rest and exercise across the three pacing states</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and Diastolic mechanical Dyssynchrony Assessment on echocardiography across the three pacing states</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rest and exercise E/E' on echocardiography across the three pacing states</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Routine Medical Therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Routine Medical Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Medical Therapy + LVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine Medical Therapy + LVP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Medical Therapy + BiVP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Routine Medical Therapy + BiVP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-pacemaker device set to Routine Medical Therapy</intervention_name>
    <description>Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy</description>
    <arm_group_label>Routine Medical Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-pacemaker device set to Routine Medical Therapy + LVP</intervention_name>
    <description>Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP</description>
    <arm_group_label>Routine Medical Therapy + LVP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-pacemaker device set to Routine Medical Therapy + BiVP</intervention_name>
    <description>Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP</description>
    <arm_group_label>Routine Medical Therapy + BiVP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical features consistent with heart failure. All patients will have symptoms of&#xD;
             moderate to severe heart failure with New York Heart Association (NHYA) classification&#xD;
             III or IV symptoms (for at least 3 months).&#xD;
&#xD;
          2. LV Ejection Fraction less or equal to 50%, with no evidence of significant valvular&#xD;
             disease, no hypertrophic or restrictive cardiomyopathy, and no evidence of pericardial&#xD;
             constriction.&#xD;
&#xD;
          3. A peak Vo2max less than 80% predicted, with respiratory exchange ratio (RER) more than&#xD;
             1 and a pattern of gas exchange on metabolic exercise testing indicating a cardiac&#xD;
             cause for limitation.&#xD;
&#xD;
          4. Additionally all patients will have demonstrated evidence of septal flattening during&#xD;
             exercise using contrast echocardiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent.&#xD;
&#xD;
          2. Enrolment in other clinical studies.&#xD;
&#xD;
          3. BMI more than 35&#xD;
&#xD;
          4. Objective evidence of significant lung disease on formal lung function testing&#xD;
&#xD;
          5. Previous (within three months) or scheduled coronary revascularisation or other&#xD;
             cardiac surgery&#xD;
&#xD;
          6. Acute coronary syndrome (within the previous three months)&#xD;
&#xD;
          7. Renal insufficiency requiring haemodialysis&#xD;
&#xD;
          8. Life expectancy less than 6 months&#xD;
&#xD;
          9. Prosthetic heart valves&#xD;
&#xD;
         10. Blood coagulation disorders&#xD;
&#xD;
         11. Immunocompromised patients (e.g. AIDS, patients on steroids, cytotoxic drugs, and&#xD;
             radiation therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matt Hammond</last_name>
    <phone>01603593617</phone>
    <email>M.hammond@uea.ac.uk</email>
  </overall_contact>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

